Edition:
United Kingdom

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

860.30INR
15 Dec 2017
Change (% chg)

Rs7.50 (+0.88%)
Prev Close
Rs852.80
Open
Rs858.50
Day's High
Rs869.00
Day's Low
Rs855.00
Volume
3,114,671
Avg. Vol
2,020,881
52-wk High
Rs1,573.60
52-wk Low
Rs806.25

Select another date:

Thu, Dec 14 2017

BRIEF-Lupin Gets U.S. FDA Nod For Generic Contraceptive Treatment

* SAYS LUPIN RECEIVES FDA APPROVAL FOR GENERIC SAFYRAL TABLETS

Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

Nov 17 Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday.

BRIEF-Lupin launches generic Acticlate tablets in U.S.‍​

* Says co launches generic Acticlate tablets in U.S.‍​ Source text: http://bit.ly/2ypyZzY Further company coverage:

UPDATE 1-India's Lupin Q2 profit falls on lower U.S. sales, but beats estimates

* U.S. sales down 32 pct (Recasts, adds details, bullets, share moves)

BRIEF-Lupin says co on track with complex generic pipeline

* Says as expected, co continues to see pricing pressure for its U.S. generic business

India's Lupin Q2 profit down 31 pct, but slightly above consensus

Oct 30 Indian drugmaker Lupin Ltd on Monday said its second-quarter profit fell about 31 percent, but the results were slightly above estimates.

BRIEF-India's Lupin Sept-qtr consol profit down 31 pct

* Sept quarter consol net profit 4.55 billion rupees versus profit of 6.62 billion rupees last year

BRIEF-Lupin gets USFDA nod for drug used in ADHD treatment

* Says Lupin receives FDA approval for generic Kapvay extended-release tablets‍​

BRIEF-Lupin gets U.S.FDA nod for generic Axirona topical solution‍​

* Says gets FDA nod for generic Axirona topical solution‍​ Source text: http://bit.ly/2xmz2rG Further company coverage:

BRIEF-India's Lupin gets U.S. FDA nod for carbidopa tablets

* Says gets U.S. FDA approval for carbidopa tablets, 25 mg Source text - http://bit.ly/2z3pjeB Further company coverage:

Select another date: